CPhI Istanbul 2015 opens as Turkey continues to dominate the MENA pharma region

Regional manufactures expanding at double-digit pace with international pharma arriving

Istanbul, 12 May 2014:CPhI Istanbul (#cphiIstanbul), organised by UBM EMEA, will return to ICC Istanbul Congress Center, Istanbul, Turkey from3 to 5 June 2015. The event now in its second year will be co-located with P-MEC, InnoPack and ICSE. Together, these four-events-in-one, provide an unrivalled meeting point for global suppliers of raw materials, machinery, packaging solutions and contract services to interact with domestic and international visitors anddeliver pharmaceutical products across Eurasia.

Turkey is fast emerging as a new hub for pharma manufacturing. This year, CPhI Istanbul will welcome more than 200 exhibitors from 23 Countries and over 4,000 visitors. The pharma market in Turkey is now valued at 14.6 billion Turkish Lira (an 8% increase from 2013) with CPhI Istanbul the integral gateway for companies looking to deliver drugs throughout Central Asia, the Middle East, North Africa and Eastern Europe. Moreover, Turkey's domestic pharma economy has over 300 companies – most of which are cGMP compliant – and produces more than 8,000 drugs. In contrast, exports have grown nearly 5% in the past year to reach a total of just under $1 billion, with South Korea, Switzerland, Germany, Iraq and Iran it's main partners.

The 2014 CPhI Pharma Insights report, produced by CPhI in collaboration with GBR, stated that many of Turkey's largest manufacturers are reporting double-digit growth rates. An updated analysis report will be launched at the 2015 event, providing attendees with vital information to help make business decisions across this diversifying region.

Gökhan Gökçe, partner at law firm YükselKarkınKüçük commenting on international interest in Turkish pharma, said: "In the coming five years we will continue to see multinational corporations invest in the Turkish market, and we know of several large global companies that are looking to make buy-ins."

To help attendees traverse the diverse range of contacts and businesses, CPhI Istanbul provides a 'Supplier Finder Desk' and 'CPhI mobile app'. These services have been specifically designed to help attendees achieve their individual business goals and to make on-site navigation easier.

Erik Heemskerk, Brand Director at UBM EMEA commented: "Turkey is the sixth largest market in Europe, and 16th largest globally. However, it is its position as the distribution hub for the entire MENA region that is attracting so much international interest. More and more companies are looking to break into what is a dynamic and reforming market and CPhI Istanbul provides the best platform to facilitate this. The event successfully brings together both domestic and international buyers and suppliers and has, undoubtedly, contributed to the continued expansion of one of the fastest developing and most vibrant pharma manufacturing economies. What is noticeable about the event's profile is the growth in the interest we are seeing from international pharma companies".

The main sponsor of the CPhI Istanbul 2015 is Deva and the event is organised with the support of the Ministry of Health (Turkish Medicines and Medical Devices Agency); the Pharmaceutical Manufacturers Association (IEIS); and KOSGEB (Republic of Turkey Small and Medium Enterprises Development Organisation).

Highlights of CPhI Istanbul 2015:
·        Co-location with P-MEC, InnoPack and ICSE providing services and opportunities through the whole supply chain;

·        Exhibitor showcases to enable attendees to learn about the newest products and services;

·        Suppliers finder desk, which allows attendees to target prescriptively products and services tailored to their needs.


-ENDS-
Notes to editors
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, Southeast Asia, Istanbul, Russia and South America and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.
For more information visit: www.cphi.com
The UBM EMEA annual schedule of Pharmaceutical events includes; CPhI Istanbul (3-5 June, 2015, at the Istanbul Convention Center, Turkey); CPhI, Hi and Fi, ICSE, P-MEC, BioPh and LabWorld China (24-26 June, 2015 at SNIEC- Shanghai, China); CPhI, ICSE Korea (7-9 September, 2015 at the COEX- Seoul, South Korea); CPhI, ICSE, P-MEC and InnoPack Worldwide (13-15 October 2015, IFEMA- Feria de Madrid, Spain); CPhI, P-MEC, ICSE and BioPh India (1-3 December, 2015 at the Bombay Convention and Exhibition Centre, Mumbai, India); CPhI, P-MEC and Innopack South East Asia (06-08 April, 2016 at the Jakarta International Expo- Jakarta, Indonesia); CPhI, ICSE, P-MEC, BioPh and InnoPack Japan (TBC April, 2016 at the Big Sight Exhibition Centre- Tokyo).
About UBM EMEA
UBM EMEA connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
For media enquiries, please contact:
Alex Heeley or Tristan Jervis  
De Facto Communications
T: +44 207 203 6745 / 6740
E: [email protected] / [email protected]

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.